<SEC-DOCUMENT>0001206774-20-001024.txt : 20200402
<SEC-HEADER>0001206774-20-001024.hdr.sgml : 20200402
<ACCEPTANCE-DATETIME>20200402083018
ACCESSION NUMBER:		0001206774-20-001024
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200401
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200402
DATE AS OF CHANGE:		20200402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		20767421

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron3746301-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">
<DIV>


<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR></FONT></B><B><FONT size=2 face="Times New Roman">WASHINGTON, D.C. 20549<BR></FONT></B><B><FONT size=2 face="Times New Roman">___________</FONT></B></P>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">FORM 8-K</FONT></B></P>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">CURRENT REPORT<BR></FONT></B><B><FONT size=2 face="Times New Roman">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>

<P style="TEXT-ALIGN: center"><FONT size=2 face="Times New Roman">Date of Report (Date of Earliest Event Reported): </FONT><B><FONT size=2 face="Times New Roman">April 1, 2020</FONT></B></P>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">GERON CORPORATION<BR></FONT></B><FONT size=2 face="Times New Roman">(Exact name of registrant as specified in its charter)<BR></FONT><B><FONT size=2 face="Times New Roman">___________</FONT></B></P>

<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>



<TR vAlign=bottom>

   <TD width="33%" noWrap align=center><B><FONT size=2 face="Times New Roman">Delaware</FONT></B></TD>

   <TD width="1%" noWrap align=center>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

   <TD width="32%" noWrap align=center><B><FONT size=2 face="Times New Roman">0-20859</FONT></B></TD>

   <TD width="1%" noWrap align=center>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

   <TD width="33%" noWrap align=center><B><FONT size=2 face="Times New Roman">75-2287752</FONT></B></TD></TR>

<TR vAlign=bottom>

   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">(State or other jurisdiction of incorporation)</FONT></TD>

   <TD width="1%" noWrap align=center><FONT size=2 face="Times New Roman"></FONT></TD>

   <TD width="32%" noWrap align=center><FONT size=2 face="Times New Roman">(Commission File Number)</FONT></TD>

   <TD width="1%" noWrap align=center><FONT size=2 face="Times New Roman"></FONT></TD>

   <TD width="33%" noWrap align=center><FONT size=2 face="Times New Roman">(IRS Employer Identification No.)</FONT></TD></TR></TABLE>


<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">919 EAST HILLSDALE BOULEVARD, SUITE 250<BR>FOSTER CITY, CA 94404<BR></FONT></B><FONT size=2 face="Times New Roman">(Address of principal executive offices, including zip code)</FONT></P>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">(650) 473-7700<BR></FONT></B><FONT size=2 face="Times New Roman">(Registrant&#8217;s telephone number, including area code)</FONT></P>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">N/A<BR></FONT></B><FONT size=2 face="Times New Roman">(Former name or former address, if changed since last report)</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</FONT></P>

<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>



<TR vAlign=bottom>

   <TD width="1%" noWrap align=left><FONT size=2 face=Arial><FONT size=2 face="Times New Roman">&#9744;</FONT></FONT></TD>

   <TD width="1%" noWrap align=left>&nbsp;&nbsp;&nbsp;</TD>

   <TD width="98%" noWrap align=left><FONT size=2 face="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>

<TR style="VERTICAL-ALIGN: bottom">

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD>

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD>

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD></TR>

<TR vAlign=bottom>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="98%" noWrap align=left><FONT size=2 face="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>

<TR style="VERTICAL-ALIGN: bottom">

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD>

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD>

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD></TR>

<TR vAlign=bottom>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="98%" noWrap align=left><FONT size=2 face="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>

<TR style="VERTICAL-ALIGN: bottom">

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD>

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD>

   <TD style="WHITE-SPACE: nowrap; TEXT-ALIGN: left">&nbsp;</TD></TR>

<TR vAlign=bottom>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">&#9744;</FONT></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="98%" noWrap align=left><FONT size=2 face="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE>


<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</FONT></P>

<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>



<TR vAlign=bottom>

   <TD STYLE="padding-right: 4pt; border: #000000 1pt solid; width: 33%; white-space: nowrap; text-align: center; padding-left: 4pt"><FONT size=2 face="Times New Roman">Title of each class</FONT></TD>

   <TD STYLE="padding-right: 4pt; border-top: #000000 1pt solid; border-right: #000000 1pt solid; border-bottom: #000000 1pt solid; width: 33%; white-space: nowrap; text-align: center; padding-left: 4pt"><FONT size=2 face="Times New Roman">Trading Symbol(s)</FONT></TD>

   <TD STYLE="padding-right: 4pt; border-top: #000000 1pt solid; border-right: #000000 1pt solid; border-bottom: #000000 1pt solid; width: 33%; white-space: nowrap; text-align: center; padding-left: 4pt"><FONT size=2 face="Times New Roman">Name of each exchange on which registered</FONT></TD></TR>

<TR vAlign=bottom>

   <TD STYLE="padding-right: 4pt; border-right: #000000 1pt solid; border-bottom: #000000 1pt solid; border-left: #000000 1pt solid; width: 33%; white-space: nowrap; text-align: center; padding-left: 4pt"><FONT size=2 face="Times New Roman">Common Stock, $0.001 par value</FONT></TD>

   <TD STYLE="padding-right: 4pt; border-right: #000000 1pt solid; border-bottom: #000000 1pt solid; width: 33%; white-space: nowrap; text-align: center; padding-left: 4pt"><FONT size=2 face="Times New Roman">GERN</FONT></TD>

   <TD STYLE="padding-right: 4pt; border-right: #000000 1pt solid; border-bottom: #000000 1pt solid; width: 33%; white-space: nowrap; text-align: center; padding-left: 4pt"><FONT size=2 face="Times New Roman">The Nasdaq Stock Market LLC</FONT></TD></TR></TABLE>


<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">Emerging growth company &#9744;</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<HR align=center SIZE=2 width="100%" noShade>



<DIV style="PAGE-BREAK-BEFORE: always"></DIV>



<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Item 8.01 Other Events.</FONT></B></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face="Times New Roman">On April 2, 2020, Geron issued a press release entitled &#8220;Geron Provides COVID-19 Related Business Update.&#8221; A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</FONT></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face="Times New Roman">Item 9.01 Financial Statements and Exhibits.</FONT></B></P>

<P STYLE="text-indent: 40pt; text-align: left"><FONT size=2 face="Times New Roman">(d) Exhibits.</FONT></P>

<DIV style="padding-left: 54pt">
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: COLLAPSE" cellSpacing=0 cellPadding=0 width="100%" border=0>



<TR vAlign=bottom>

   <TD STYLE="width: 1%; white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><B><FONT size=2 face="Times New Roman">Exhibit No.</FONT></B></TD>

   <TD STYLE="width: 1%; white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT size=2 face="Times New Roman"></FONT></B></TD>

   <TD STYLE="width: 98%; white-space: nowrap; text-align: left; border-bottom: Black 1pt solid"><B><FONT size=2 face="Times New Roman">Description</FONT></B></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">

   <TD width="1%" noWrap align=center><A HREF="geron3746301-ex991.htm" STYLE="-sec-extract: exhibit"><FONT size=2 face="Times New Roman">99.1</FONT></A></TD>

   <TD width="1%" noWrap align=center><FONT size=2 face="Times New Roman"></FONT></TD>

   <TD width="98%" noWrap align=left><A HREF="geron3746301-ex991.htm" STYLE="-sec-extract: exhibit"><FONT size=2 face="Times New Roman">Press release dated April 2, 2020.</FONT></A></TD></TR></TABLE>

</DIV>
<P style="TEXT-ALIGN: center"><FONT size=3 face="Times New Roman">1</FONT></P>

<HR align=center SIZE=2 width="100%" noShade>



<DIV style="PAGE-BREAK-BEFORE: always"></DIV>



<P style="TEXT-ALIGN: center"><B><FONT size=2 face="Times New Roman">SIGNATURE</FONT></B></P>

<P STYLE="text-indent: 15pt; text-align: left"><FONT size=2 face="Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>

<TABLE style="LINE-HEIGHT: normal" cellSpacing=0 cellPadding=0 width="100%" border=0>



<TR vAlign=bottom>

   <TD width="50%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

   <TD width="49%" colSpan=3 noWrap align=left><FONT size=2 face="Times New Roman"></FONT><FONT size=2 face="Times New Roman">GERON CORPORATION</FONT></TD>


   </TR>

<TR>

   <TD width="100%" colSpan=5>&nbsp;</TD></TR>

<TR vAlign=bottom>

   <TD width="50%" noWrap align=left><FONT size=2 face="Times New Roman">Date: April 2, 2020</FONT></TD>

   <TD width="1%" noWrap align=left>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">By:&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>

   <TD COLSPAN="2" STYLE="width: 48%; white-space: nowrap; text-align: left; border-bottom: Black 1pt solid"><FONT size=2 face="Times New Roman">/s/ Stephen N. Rosenfield</FONT></TD></TR>

<TR vAlign=bottom>

   <TD width="50%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>

   <TD width="47%" noWrap align=left><FONT size=2 face="Times New Roman">Stephen N. Rosenfield</FONT></TD></TR>

<TR vAlign=bottom>

   <TD width="50%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman"></FONT></TD>

   <TD width="1%" noWrap align=left><FONT size=2 face="Times New Roman">Title:</FONT></TD>

   <TD width="47%" noWrap align=left><FONT size=2 face="Times New Roman">Executive Vice President,</FONT></TD></TR>

<TR vAlign=bottom>

   <TD width="50%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="47%" noWrap align=left><FONT size=2 face="Times New Roman">Chief Legal Officer and</FONT></TD></TR>

<TR vAlign=bottom>

   <TD width="50%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="1%" noWrap align=left></TD>

   <TD width="47%" noWrap align=left><FONT size=2 face="Times New Roman">Corporate Secretary</FONT></TD></TR></TABLE>


<P style="TEXT-ALIGN: center"><FONT size=3 face="Times New Roman">2</FONT></P>

<HR align=center SIZE=2 width="100%" noShade>
</DIV>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>geron3746301-ex991.htm
<DESCRIPTION>PRESS RELEASE DATED APRIL 2, 2020
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">
<DIV>

<P STYLE="text-align: right"><B><FONT size=2 face=Arial>EXHIBIT 99.1</FONT></B></P>

<P style="TEXT-ALIGN: center"><B><FONT size=2 face=Arial>Press Release Dated April 2, 2020</FONT></B></P>

<IMG border=0 src="geron3746301-ex991x1x1.jpg">

<P style="TEXT-ALIGN: center"><B><FONT size=2 face=Arial>Geron Provides COVID-19 Related Business Update</FONT></B></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face=Arial>MENLO PARK, Calif., April 2, 2020 </FONT></B><FONT size=2 face=Arial>&#8211; Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from its March 12 year-end conference call related to the impact of the COVID-19 pandemic on the Company&#8217;s business, and described the measures being taken to protect the safety of Geron&#8217;s employees and patients in its clinical trials.</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>&#8220;We remain committed to advancing our imetelstat development plans, but recognize the unprecedented challenges created by the COVID-19 pandemic,&#8221; said John A. Scarlett, M.D., Chairman and Chief Executive Officer. &#8220;Like many other drug development companies, our clinical trial activities are being impacted in countries where healthcare systems are severely affected by the COVID-19 pandemic. Due to these circumstances, we no longer expect to complete enrollment in the IMerge Phase 3 trial or to commence our proof of concept study in high risk MDS and AML by the end of 2020, as we had originally planned. Given the fluid and rapidly evolving consequences of COVID-19, we cannot predict the long-term effect on IMerge timelines until we have more visibility on the length of the crisis and its impact on our IMerge clinical trial activities. We continue to monitor this situation and will provide an update on our next quarterly conference call.&#8221;</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Geron&#8217;s Chief Financial Officer, Olivia Bloom added, &#8220;To actively conserve our financial resources during these uncertain times, we have implemented measures to manage our near-term cash burn, and expect our spending in 2020 will be lower than the $70 to $75 million we previously guided. We plan to update our 2020 spending guidance, to the extent practicable, on our next quarterly conference call.&#8221;</FONT></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face=Arial>Geron Business Updates</FONT></B></P>

<P style="TEXT-ALIGN: left"><U><FONT size=2 face=Arial>Ongoing Operations</FONT></U></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>The Company has taken steps to ensure the safety and well-being of its employees. In compliance with local &#8216;stay at home&#8217; measures and to limit the risk of exposure to and transmission of COVID-19, Geron has suspended all business travel and implemented a work from home policy for all employees. To enable business to continue virtually, Geron has made technology resources available to all employees.</FONT></P>

<P style="TEXT-ALIGN: left"><U><FONT size=2 face=Arial>IMerge Phase 3 Clinical Trial</FONT></U></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Geron is planning to open more than 90 sites globally for the IMerge Phase 3 clinical trial. As of the end of March, 66% of the total sites were open in the United States, Europe, Middle East and Asia. Geron has provided guidance to IMerge investigators regarding COVID-19 intended to ensure the safety of patients while preserving the integrity of the trial.</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>COVID-19 related challenges have led to delays in new site initiations and enrollment. As a result, the Company no longer expects to complete enrollment in IMerge by year-end 2020, as previously disclosed. Geron continues to monitor this situation and expects to provide an update on its next quarterly conference call.</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>As previously disclosed, the Company has sufficient drug supply for the ongoing IMerge clinical trial.</FONT></P>

<P style="TEXT-ALIGN: left"><U><FONT size=2 face=Arial>Potential Registration Strategy for Imetelstat in Myelofibrosis (MF)</FONT></U></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Geron currently has a scheduled meeting with the U.S. Food and Drug Administration (FDA) in the second quarter to discuss a potential regulatory approval path for imetelstat in MF. Geron expects to announce its decision regarding any potential late-stage development plans for MF by mid-year 2020.</FONT></P>

<HR align=center SIZE=2 width="100%" noShade>



<DIV style="PAGE-BREAK-BEFORE: always"></DIV>



<P style="TEXT-ALIGN: left"><U><FONT size=2 face=Arial>Managing 2020 Operating Expenses</FONT></U></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>In response to the COVID-19 pandemic, Geron has implemented measures to manage its cash burn, including suspending travel and in-person meeting attendance, as well as re-evaluating its near-term hiring plan.</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>With these measures, as well as the anticipated delays in both completing IMerge enrollment and commencement of the proof of concept study in high risk MDS and acute myeloid leukemia (AML), the Company expects its 2020 operating expense burn to be lower than the previously disclosed guidance of $70 to $75 million. Geron plans to update 2020 operating expense burn guidance on its next quarterly conference call.</FONT></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face=Arial>About Imetelstat</FONT></B></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the apoptosis of malignant stem and progenitor cells, which allows potential recovery of normal hematopoiesis. Clinical studies of imetelstat sponsored by Geron include IMerge, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS), and IMbark, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis (MF). Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower risk MDS who are refractory or resistant to an erythropoiesis-stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.</FONT></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face=Arial>About Geron</FONT></B></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.</FONT></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face=Arial>Use of Forward-Looking Statements</FONT></B></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Except for statements of historical fact, the statements contained in this press release are forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the expectations, plans, timelines, beliefs, potential and prospects for imetelstat and Geron, including, without limitation, statements related to: (i) that imetelstat may have disease-modifying activity; (ii) that Geron plans to discuss a potential regulatory approval path with the FDA in the second quarter and to make a decision by mid-year 2020 regarding any potential late-stage development of imetelstat in MF; (iii) that Geron&#8217;s 2020 operating expense burn will be lower than the $70-$75 million that was previously guided; (iv) that Geron expects to update the timing for completion of enrollment in IMerge, commencement of the high risk MDS and AML proof of concept study and its financial guidance at its next quarterly conference call; and (v) other statements that are not historical facts. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, the following: (a) regulatory authorities may not permit the further development of imetelstat for MF and/or MDS and/or potential additional indications on a timely basis, or at all, and may impose clinical holds; (b) after interactions with the FDA, Geron may decide not to pursue further development of imetelstat in MF; (c) imetelstat may not demonstrate successful efficacy and safety in clinical trials; (d) Geron may be unable to project or attain complete enrollment of IMerge due to circumstances caused by the COVID-19 pandemic, such as: lack of patients, regulatory holds, insufficient number of sites, and/or unavailability of drug; (e) there may be failures or delays in manufacturing sufficient quantities of imetelstat, or other clinical trial materials, in a manner that meets the quality standards of the FDA and other regulatory authorities; (f) Geron may not be able to obtain sufficient funding to support further development of imetelstat; (g) imetelstat may fail to demonstrate in clinical trials that it has disease-modifying activity; and (h) Geron may decide not to start a proof-of-concept study in high risk MDS and AML. Additional information and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron's periodic reports filed with the Securities and Exchange Commission under the heading &#8220;Risk Factors,&#8221; including in Geron's annual report on Form 10-K for the year ended December 31, 2019 and in subsequent filings on Form 8-K. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial></FONT></P>

<P style="TEXT-ALIGN: left"><B><FONT size=2 face=Arial>CONTACT:</FONT></B></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>Suzanne Messere<BR>Investor and Media Relations<BR>investor@geron.com<BR>media@geron.com</FONT></P>

<P style="TEXT-ALIGN: left"><FONT size=2 face=Arial>CG Capital<BR>877-889-1972</FONT></P>

<P style="TEXT-ALIGN: center"><FONT size=2 face=Arial>###</FONT></P>

<HR align=center SIZE=2 width="100%" noShade>




</DIV>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron3746301-ex991x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron3746301-ex991x1x1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S &$# 2(  A$! Q$!_\0
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MD3)5V!\+_P"#VR&(_LV_L(SF*(W$?[0/Q$ACG,:&:.*7P%IKRQ),1YB12O!
M\J*P21X86=2T<94 _MNN[ZST^RNM2O;F"TT^RM9[Z\O9Y$BMK:SMH6GN+J:9
MR(T@A@1I9)68(D:LQ( )K^%7Q#_P76_X+/\ _!3;]JCXY?##_@B'\"_AUJO[
M/GP/OYDMOBCXP\*^&QK7BK1[:673['7O%'BKXP^+=$^'^@R>.;^RO[_P3X%T
MO1[;Q?\ V%&;G4);AK+59;#^R;XMLW_#(OQ-8,=W_#./C1MV2&W?\*RU([MV
M<@YYSG.><U_,_P#\&7D,*?\ !+3XR3K#$L\W[;OQ,CFF6-%FECA^#7[/YA26
M4 /(D)FE,2LQ6,RR% #(V0#UG_@AS_P7,^/_ .V'^T'\8/\ @GE_P43^$6@?
M W]MSX.:7JVL6*Z3I>I>#X?'MOX9O88/&/AK5_!&K7VJIHGC;PWI^H:5XCM+
MG0-8N]!\7^%9=2UO3-/TJUT83ZO^[7[=/[;'P2_X)Z_LQ_$?]JKX_:E?VO@+
MX>VEBD>C:&EC<^*_&?B;6[Z'2_#G@SP?IM_?:=;ZEXAUS4;A$BBDO+>VL=/@
MU'6M2GM=)TO4+N#^/G6$2+_@]\TTQ(L?F^"-/>7RU">:[_\ !.PAGDV@>8S!
M5#,V6(4#)P!7UC_P>H22+_P3=_9[C61UCD_;'\*^8@=@DFSX0?& IYB@[7VD
MDH7!VDD@@G- 'Q9\,_\ @XS_ ."\G[;FM:EXS_85_P""8'@O7_@/9^)O[-BU
M]?A5\:?BI+:V+:@8GLM1^(]GX_\ A]X+UC7+&R^;4;?0M M6LYQNGMXXGC#?
MNI_P7>_X+;2?\$EO@S\*-'^'7@/1OB;^UQ^T')>1?#+P+XFM=:F\&^'M%T)-
M.MO$_C'Q5;:#?6&M:H8-:UG2-"\,^%-/U/3[SQ!J5U>RMJ=O;:)=1W?Z0?\
M!+CPWH7A+_@FK^P!H7AO2[/1](M_V-/V:KR*QL84@@%YJ_P?\(:SJMVR( 'N
MM2U:_OM2O[ALRW5]=W%U,SS3.Q_D3_X.9U67_@N1_P $6X95$L+Z[\!U>*0!
MXG63]KVQ216C<%6$B *X92&4!6!  H YGXH_\%G?^#EK_@F]I?PM_:2_X*"?
MLI?"S7_V9OB?JND+=:3)X+\,Z-/X<@UE%U"W\*:AXC^%7C'4M9^$WCB_TMI3
MH%C\6=,U262]M;BQN=*OM1T_4[&'^ZWX'?&3P)^T1\&OA9\>/A?J@UGX>?&'
MP!X4^)'@S43Y:S3^'_&&BV>N::E[##-.EIJ5K!>+::K8-*\VGZC!=6,Y6>WD
M4?BQ_P '0,4<G_!$+]LTR1QR&(? R6,R(KF.0?M$?"E1)'N!V2!790ZX8*S
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M\HZ_V!_^S+/V6?\ U1O@6OX^/^#F/_E.9_P1:_[#WP$_]:_LJ /WB_X.?_\
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E22N44 ?<@_J?T)I:** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
